CAV1 and cardiac rhythm disease: These experiments demonstrate the feasibility of targeting Ca(v)1.2 α1C subunit palmitoylation to suppress lethal cardiac arrhythmias and highlight the potential therapeutic applications of enzyme-nanobody chimeras.